Similar findings were observed for PFS in the small subset of patients with KRAS G12C-mutated lung cancer (N = 37) in KEYNOTE 189, but, in contrast to our study, no promising OS benefit was observed for the ICI combination.24 The gene discussed is KRAS; the disease is lung carcinoma.